CMND

Clearmind Medicine Inc

6.06

Oct 28 • 3:59 PM ET +0.09 (1.55%)

6.10

Aftermarket • 7:53 PM ET +0.04 (0.66%)

Healthcare Biotechnology Canada Nano NASD

Oct 27, 8:25 AMClearmind Medicine announces it has completed patient recruitment for the first Alcohol Use Disorder cohort in Part B of its Phase I/IIa clinical trial of CMND-100.

Peers: ADIL ENVB PBM DRUG SILO GHRS ACHV VTGN MNOV KTTA

Scroll to Statements

Index	-
Market Cap	3.08M
Enterprise Value	-11.05M
Income	-7.50M
Sales	0.00M
Book/sh	48.30
Cash/sh	31.37
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	-
IPO	Aug 16, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	0.13
P/C	0.19
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	4.31
Current Ratio	4.31
Debt/Eq	0.14
LT Debt/Eq	0.01
Option/Short	No / Yes

EPS (ttm)	-705.15
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	83.49% 39.75%
Sales past 3/5Y	- -
EPS Y/Y TTM	74.01%
Sales Y/Y TTM	-
EPS Q/Q	99.42%
Sales Q/Q	-
Earnings	-
EPS/Sales Surpr.	- -

Insider Own	0.04%
Insider Trans	-
Inst Own	9.66%
Inst Trans	-
ROA	-71.81%
ROE	-106.98%
ROIC	-57.44%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-1.37%
SMA50	-28.06%
SMA200	-87.83%
Trades

Shs Outstand	0.27M
Shs Float	0.06M
Short Float	6.44%
Short Ratio	0.07
Short Interest	0.00M
52W High	3840.00 -99.84%
52W Low	5.25 15.43%
Volatility	3.87% 7.57%
ATR (14)	0.50
RSI (14)	38.82
Beta	-1.12
Rel Volume	0.09
Avg Volume	58.72K
Volume	5,130

Perf Week	2.02%
Perf Month	-6.64%
Perf Quarter	-53.24%
Perf Half Y	-89.12%
Perf YTD	-95.81%
Perf Year	-99.81%
Perf 3Y	-99.95%
Perf 5Y	-100.00%
Perf 10Y	-
Recom	-
Target Price	-
Prev Close	5.97
Price	6.06
Change %	1.55%

Oct-27-26 08:22AM	Clearmind Successfully Completes Patient Recruitment for the First Alcohol Use Disorder Cohort of its CMND-100 Phase I/IIa Clinical Trial (GlobeNewswire)
Oct-16-26 10:44AM	What Is The Case For Waiting On Moderna Stock? (Trefis)
Oct-12-26 05:01PM	Where Could Moderna's Next Growth Come From? (Trefis)
07:55AM	Clearmind: Charging Robotics Launches Next-Generation Automated EV-Charging Technology for Robotaxis and Autonomous Fleets (GlobeNewswire)
Oct-08-26 07:32AM	Clearmind Announces Patent Publication in Japan Covering Treatment for Neurological Movement Disorder (GlobeNewswire)
08:40AM	Loading…
Oct-07-26 08:40AM	Clearmind Advances Dialogue with U.S. Federal Government on Psychedelic Therapies, Submitting Recommendations to FDA (GlobeNewswire) +13.01%
Sep-23-26 09:05AM	NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration With Clearmind Covering LSD, Ketamine and Ibogaine Combinations (NewMediaWire) +8.81%
07:57AM	Clearmind Enhances U.S. IP Presence with Publication of Three Patent Applications Covering LSD, Ketamine and Ibogaine Combinations (GlobeNewswire)
Sep-17-26 07:42AM	Clearmind Medicine Delivers Briefing to FDA Following Invitation to Historic Psychedelic Hearing in Washington, D.C. (GlobeNewswire) +6.46%
Sep-11-26 08:00AM	Clearmind Enrolls First Patients with Alcohol Use Disorder in CMND-100 Clinical Trial (GlobeNewswire)
Sep-08-26 07:42AM	Clearmind Medicine Receives Yale IRB Approval, Enabling Patient Recruitment for Parts B and C of CMND-100 Phase I/II Trial, Following Positive Safety Results (GlobeNewswire) -11.21%
Sep-04-26 09:55AM	Clearmind Medicine Agrees to Acquire 51% Stake in Charging Robotics for $2.5 Million (InvestorsHub) -31.76%
07:32AM	Clearmind Medicine Signs Definitive Agreement to Acquire 51% Stake in Wireless Charging Company for Automated Parking and Robotaxis (GlobeNewswire)
Sep-01-26 07:37AM	Clearmind Reaches Key Milestone: CMND-100 Phase IIa now Underway for Alcohol Use Disorder Trial, One-Third of Part C Enrolled (GlobeNewswire) -5.67%
Aug-24-26 08:55AM	NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation (NewMediaWire)
08:03AM	Loading…
08:03AM	Clearmind Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation (GlobeNewswire)
Aug-13-26 07:36AM	Clearmind Advances CMND-100 to Alcohol Use Disorder Patients After Achieving Primary Safety Endpoint (GlobeNewswire) +12.12%
Aug-11-26 08:05AM	Clearmind Medicine Announces Positive Permeation Results for Intranasal MEAI Formulation, Supporting Enhanced Nasal Retention Without Compromising Drug Delivery (GlobeNewswire)
Aug-06-26 08:00AM	Clearmind Reaches Key Clinical Trial Milestone as DSMB Unanimously Clears Progression in AUD Study (GlobeNewswire)
Aug-03-26 08:02AM	Clearmind Medicine Signs Letter of Intent to Acquire 51% Majority Stake in EV Wireless Charging Solutions for Automated Parking Systems Company (GlobeNewswire)
Aug-02-26 06:26PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Jul-30-26 08:30AM	Clearmind Announces Positive Safety Findings for CMND 100, Demonstrating Consistent Tolerability Throughout Full Dose Escalation in Part A of its FDA-Regulated Clinical Trial (GlobeNewswire) +10.96%
Jul-28-26 07:47AM	Clearmind Medicine Successfully Completes Part A of its FDA Regulated Phase I/II Trial (GlobeNewswire) -9.88%
Jul-20-26 07:55AM	Clearmind Medicine Expends Global IP portfolio with Hong Kong Patent Filing for Novel Psychedelic Compounds; Targets Multi-Billion-Dollar PTSD Therapeutics Market (GlobeNewswire)
Jul-17-26 07:32AM	Clearmind Medicine Commends Federal Momentum in Advancing Psychedelic-Based Therapies for Mental Health and Addiction (GlobeNewswire)
Jul-16-26 09:30AM	Clearmind Medicine Reports Positive Retention Results for Intranasal Formulation of its Psychedelic-Based Neuroplastogen MEAI (GlobeNewswire) +9.34%
Jul-13-26 08:17AM	Clearmind Shares Promising Real-World Insights from Ongoing CMND-100 First-in-Human Trial (GlobeNewswire)
Jul-10-26 08:32AM	Clearmind Medicine Responds to the U.S. Administration's RFI for Addiction Treatment Innovations as Part of the Great American Recovery Initiative (GlobeNewswire)
Jul-07-26 07:42AM	Clearmind Reports Successful Formulation Feasibility Study Supporting Potential New Additional Route of Administration Development for MEAI (GlobeNewswire) -9.40%
Jul-06-26 03:53PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
07:55AM	Loading…
Jun-29-26 07:55AM	Clearmind Medicine Advances Its Innovation with Newly Granted U.S. Patent, Enhancing Global Patent Strength (GlobeNewswire)
Jun-22-26 08:07AM	Clearmind Medicine Reaches Major Milestone, Completing Part A Treatment in FDA-Regulated Phase I/II Trial (GlobeNewswire)
Jun-18-26 07:55AM	Clearmind Medicine Granted U.S. Patent for Binge Behavior Regulators (GlobeNewswire)
Jun-16-26 07:32AM	Clearmind Medicine Completes Dosing for Part A of its of FDA-Regulated Phase I/II Clinical Trial (GlobeNewswire) -6.82%
Jun-08-26 02:41PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Jun-05-26 07:32AM	Clearmind Medicine to Feature New Insights from CMND-100 Psychedelic Clinical Trial on "Inside MEAI" Webinar (GlobeNewswire) +36.77%
May-29-26 11:04AM	Why Did CMND Stock Jump 40% Today? (Stocktwits) +46.12%
08:32AM	Clearmind Medicine Advances Global Intellectual Property Portfolio with Japanese Patent Filing for Innovative Psychedelic- Based Depression Treatment (GlobeNewswire)
May-26-26 08:25AM	Clearmind Medicine Announces Johns Hopkins IRB Approval to Advance CMND-100 Phase I/II Clinical Trial to the Next Parts (GlobeNewswire) +14.60%
May-19-26 06:00AM	Clearmind Medicine Announces 1-for-10 Reverse Share Split (GlobeNewswire) -37.83%
May-18-26 11:17AM	Tirzepatide Combination Study Expands Clearminds Obesity Therapy Strategy (CMND) (InvestorsHub) -26.90%
10:30AM	BC-Most Active Stocks (Associated Press)
08:42AM	Clearmind Medicine Signs Agreement to Examine MEAI in Combination and Sequencing with Tirzepatide Against Blockbuster GLP-1 Medications (GlobeNewswire)
May-15-26 08:35AM	Clearmind Medicine CEO Dr. Adi Zuloff-Shani named Delegate to Federal Policy Summit on Psychedelic Medicine in Washington, D.C. (GlobeNewswire)
May-12-26 08:41AM	Clearmind Medicine Reaches Important Clinical Milestone: 20 Participants Now Treated in Ongoing Phase I/IIa Trial of CMND-100 for Alcohol Use Disorder (GlobeNewswire)
May-11-26 07:55AM	Clearmind Medicine Announces "Inside MEAI" Webinar Featuring New Insights from CMND-100 Psychedelic Clinical Trial (GlobeNewswire) -5.56%
May-05-26 08:50AM	Clearmind Medicine Announces Filing of European Patent Application for Novel Psychedelic Compounds for the Treatment of PTSD (GlobeNewswire) -9.56%
Apr-27-26 09:16AM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive) -10.09%
07:41AM	Clearmind Medicine Announces Evaluation of its Psychedelic-Based Treatment (MEAI) for Potential FDA Breakthrough Therapy Designation (GlobeNewswire)
Apr-20-26 04:03PM	Clearmind Medicine Welcomes President Trump's Executive Order as a Historic Catalyst for Psychedelic Innovation and Veteran Mental Health Care (GlobeNewswire) +58.42% -28.07%
10:30AM	BC-Most Active Stocks (Associated Press)
07:15AM	Clearmind Medicine Announced Positive Top-Line Safety Results: CMND-100 Proprietary Psychedelic Treatment Meets Primary Endpoint in AUD Trial (GlobeNewswire)
Apr-15-26 07:30AM	Clearmind Medicine Announces Positive Data Safety Monitoring Board Recommendation in ongoing CMND-100 clinical trial (GlobeNewswire) -28.57%
Apr-14-26 10:30AM	BC-Most Active Stocks (Associated Press) -36.36%
07:32AM	Clearmind Medicine's CMND-100 Meets Primary Endpoint in FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder (GlobeNewswire)
Mar-30-26 08:32AM	Clearmind Medicine Announces Successful Completion of Treatment and Follow-up for 18 Participants in its Ongoing Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder (GlobeNewswire) +22.70%
Mar-27-26 07:32AM	Clearmind Medicine Files Patent Application in India for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders (GlobeNewswire) +10.41%
Mar-19-26 08:45AM	Clearmind Medicine Reports Successful Ongoing Treatment of Participants at US Sites in its FDA-approved CMND-100 Phase I/IIa Clinical Trial for Alcohol Use Disorder (GlobeNewswire)
Mar-17-26 09:15AM	Clearmind Medicine Announces Publication of Six Innovative Patents in Hong Kong for Next-Generation Psychedelic-Based Combination Therapies (GlobeNewswire)
Mar-16-26 07:30AM	NeuroThera Labs - Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy (NewMediaWire) -5.13%
Mar-13-26 07:45AM	Clearmind Medicine Announces Hong Kong Patent Filing for Depression Therapy (GlobeNewswire) -5.88%
Mar-11-26 09:07AM	Clearmind Medicine Advances Recruitment for CMND-100 Trial's Third Cohort at Yale, Johns Hopkins and Tel Aviv Sites Following Recent Positive Topline Results (GlobeNewswire) -6.28%
07:30AM	NeuroThera Labs Announces Publication of International Patent in Collaboration With Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease (NewMediaWire)
Mar-10-26 08:59AM	Clearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver Disease (GlobeNewswire)
Mar-06-26 10:15AM	Psychedelic: Helus Pharma reports HLP004 Phase 2 signal detection study results (TipRanks) +5.56%
Mar-04-26 07:30AM	Clearmind Medicine Moving Forward to the Next Stage of Its Clinical Trial Following Data and Safety Monitoring Board Approval (GlobeNewswire)
Feb-19-26 01:05PM	Moonage Media Review: Clearmind's MEAI and GLP-1 - Are These the Next-Generation Treatment for Weight Loss? (PR Newswire)
Feb-16-26 02:58PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Feb-09-26 08:17AM	Clearmind Medicine Announces Additional Topline Positive Safety Results Reinforcing Favorable Profile of CMND-100 in Ongoing Phase I/IIa Clinical Trial (GlobeNewswire) -8.15%
Feb-08-26 03:50PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Feb-06-26 07:55AM	Clearmind Medicine Enters into Development Agreement to Advance Intranasal Formulation for its Proprietary Non-Hallucinogenic Neuroplastogen MEAI (GlobeNewswire) -6.90%
Feb-03-26 08:00AM	Excellent Achievements for Clearmind's Proprietary MEAI that was Included in U.S. Congress' Emerging Therapies Bill to Expand Veteran Access to Innovative Treatments (GlobeNewswire) -5.83%
Jan-20-26 04:20PM	Clearmind Medicine Inc. Files Annual Report on Form 20-F for the Fiscal Year Ended October 31, 2025 (GlobeNewswire) +5.60%
Jan-14-26 08:55AM	Clearmind Medicine Announces Successful Completion of Treatment in All Patients of the Second Cohort in Ongoing Phase I/IIa Clinical Trial for CMND-100 (GlobeNewswire)
Dec-31-25 09:10AM	Clearmind Medicine Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire)
Dec-24-25 09:15AM	Clearmind Medicine Reflects on a Transformative 2025: Key Clinical Advancements, Expanded Global Reach, and Strengthened Foundation for Future Growth (GlobeNewswire) -5.76%
Dec-16-25 08:45AM	Clearmind Medicine Announces Successful Completion of Second Cohort Enrollment in Ongoing FDA-Approved Phase I/IIa Trial for CMND-100 (GlobeNewswire)
Dec-15-25 08:03AM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive) -8.48%
Dec-12-25 08:32AM	Clearmind Medicine's MEAI Spotlighted in Prestigious Review: Leading Experts Affirm Transformative Potential for Alcohol Use Disorder Treatment (GlobeNewswire)
06:32AM	Clearmind Medicine Successfully Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement (GlobeNewswire)
Dec-10-25 04:15PM	Clearmind Medicine Announces 1-for-40 Reverse Share Split (GlobeNewswire) -6.08% -37.27%
Dec-05-25 05:00PM	Clearmind Medicine Announces Receipt of Nasdaq Minimum Bid Price Notification (GlobeNewswire)
Dec-02-25 07:57AM	Clearmind Medicine Advances CMND-100 to Dosing Phase at Hadassah Medical Center in Ongoing Phase I/IIa Clinical Trial for Alcohol Use Disorder (GlobeNewswire) -9.94%
Dec-01-25 08:56AM	Clearmind Medicine Charges Forward in Alcoholism Treatment: Positive Cohort Data, Full DSMB Approval, and New Elite Site Joins the Clinical Trial (GlobeNewswire) -6.92%
Nov-25-25 07:17AM	Clearmind Medicine Kicks-Off Patient Enrollment at Tel Aviv Sourasky Medical Center, Adding Another Site Activated in its in Phase I/IIa Alcohol Use Disorder Trial (GlobeNewswire) -19.40%
Nov-24-25 08:51AM	Clearmind Medicine's Data and Safety Monitoring Board Unanimously Approves Continuation of Phase I/IIa Clinical Trial for CMND-100 Following Positive Interim Safety Review (GlobeNewswire) +8.41%
Nov-23-25 01:22PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Nov-20-25 06:01AM	Clearmind Medicine Accelerate FDA-Approved Alcohol Use Disorder Clinical Trial by Activating Fifth Elite Global Medical Site (GlobeNewswire)
Nov-19-25 10:35AM	Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression (NewMediaWire) -6.42%
Nov-18-25 08:56AM	Clearmind Medicine Announces Positive Top-Line Results from First Cohort of its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder (GlobeNewswire) -21.85%
Nov-17-25 07:55AM	Clearmind Medicine Files Israeli Patent for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression (GlobeNewswire)
Nov-13-25 08:54AM	Clearmind Medicine Receives Final Approval to Expand its FDA Regulated Phase 1/2a Clinical Trial for Alcohol Use Disorder at Hadassah Medical Center (GlobeNewswire) +11.57%
Nov-12-25 06:25AM	Clearmind Medicine Announces Notice of Patent Publication for Depression Treatment (GlobeNewswire) -32.32%
Nov-10-25 08:07AM	Clearmind Medicine Successfully Completed First Cohort Treatment in its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder (GlobeNewswire)
Nov-06-25 04:02PM	Clearmind Medicine Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency (GlobeNewswire) -5.75% -7.70%
Nov-05-25 06:55AM	Clearmind Expands Global IP Protection for MEAI in Depression Treatment with New South Korea Patent Filing (GlobeNewswire)
Nov-02-25 04:32PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Oct-31-25 07:35AM	Clearmind Medicine Advances Fight Against Cocaine Addiction with Publication of U.S. Patent Application for Its Non-Hallucinogenic Neuroplastogen MEAI Therapy (GlobeNewswire) -12.28%
Oct-30-25 07:55AM	Clearmind Medicine Completes First Cohort Treatment in its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder (GlobeNewswire) -9.30%
Oct-28-25 08:08AM	Clearmind Medicine CEO Dr. Adi Zuloff-Shani to Speak at Women in Psychedelic Leadership Webinar (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
HRT FINANCIAL LP	10% Owner	Jun 16 '26	Sale	3.31	22,139	73,192	81,353	Jun 18 05:05 PM
HRT FINANCIAL LP	10% Owner	Jun 15 '26	Sale	3.32	3,183	10,568	103,492	Jun 17 04:42 PM
HRT FINANCIAL LP	10% Owner	Jun 12 '26	Sale	3.36	2,102	7,063	106,675	Jun 16 09:19 AM
HRT FINANCIAL LP	10% Owner	Jun 10 '26	Buy	0.15	2,159,052	330,335	2,063,266	Jun 12 04:28 PM
HRT FINANCIAL LP	10% Owner	Jun 11 '26	Sale	0.12	225,191	27,698	1,838,075	Jun 12 04:28 PM

Clearmind Medicine, Inc. is a psychedelic pharmaceutical biotech company. It focuses on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize it as regulated medicines, foods, or supplements. The company was founded on July 18, 2017 and is headquartered in Vancouver, Canada.

Chief Executive OfficerDr. Adi Zuloff-Shani Ph.D.

B.CommMr. Alan Mark Rootenberg B.Com.

Vice President of Business DevelopmentProf. Mark Haden M.S.W.

Accounting ManagerMs. Mylene Touboul

Chief of Global ImpactMs. Mary-Elizabeth Gifford

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CMND

Clearmind Medicine Inc

Upgrade your Finviz experience